Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Philippe Azulay

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Neuro-Degenerative Diseases|May 22, 2019
Psychosocial Impact of Dysarthria: The Patient-Reported Outcome as Part of the Clinical ManagementCyril Atkinson-Clement, Alban Letanneux, Guillaume Baille, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 28, 2021
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a TrialJean-Christophe Corvol, Jean-Philippe Azulay, Björn Bosse, et al.
Journal of Neurology|April 10, 2016
Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort studySophie Drapier, Alexandre Eusebio, Bertrand Degos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 12, 2010
Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over studyOlivier Rascol, Jean-Philippe Azulay, Olivier Blin, et al.
Neurobiology of Disease|June 18, 2018
Beta burst coupling across the motor circuit in Parkinson's diseaseGerd Tinkhauser, Flavie Torrecillos, Yann Duclos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trialDavid Devos, Caroline Moreau, David Maltête, et al.
Journal of Parkinson'S Disease|May 9, 2022
Early Parkinson's Disease Phenotypes Tailored by Personality, Behavior, and Motor SymptomsBruna Meira, Eugénie Lhommée, Emmanuelle Schmitt, et al.
Journal of Parkinson'S Disease|March 7, 2022
Fatigue in de novo Parkinson's Disease: Expanding the Neuropsychiatric Triad?Matthieu Béreau, Anna Castrioto, Eugénie Lhommée, et al.
Neurology|December 28, 2013
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trialFabienne Ory-Magne, Jean-Christophe Corvol, Jean-Philippe Azulay, et al.
Plos One|January 24, 2014
Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohortGaëlle Désaméricq, Guillaume Dolbeau, Christophe Verny, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Neuro-Degenerative Diseases|May 22, 2019
Psychosocial Impact of Dysarthria: The Patient-Reported Outcome as Part of the Clinical ManagementCyril Atkinson-Clement, Alban Letanneux, Guillaume Baille, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 28, 2021
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a TrialJean-Christophe Corvol, Jean-Philippe Azulay, Björn Bosse, et al.
Journal of Neurology|April 10, 2016
Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort studySophie Drapier, Alexandre Eusebio, Bertrand Degos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 12, 2010
Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over studyOlivier Rascol, Jean-Philippe Azulay, Olivier Blin, et al.
Neurobiology of Disease|June 18, 2018
Beta burst coupling across the motor circuit in Parkinson's diseaseGerd Tinkhauser, Flavie Torrecillos, Yann Duclos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trialDavid Devos, Caroline Moreau, David Maltête, et al.
Journal of Parkinson'S Disease|May 9, 2022
Early Parkinson's Disease Phenotypes Tailored by Personality, Behavior, and Motor SymptomsBruna Meira, Eugénie Lhommée, Emmanuelle Schmitt, et al.
Journal of Parkinson'S Disease|March 7, 2022
Fatigue in de novo Parkinson's Disease: Expanding the Neuropsychiatric Triad?Matthieu Béreau, Anna Castrioto, Eugénie Lhommée, et al.
Neurology|December 28, 2013
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trialFabienne Ory-Magne, Jean-Christophe Corvol, Jean-Philippe Azulay, et al.
Plos One|January 24, 2014
Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohortGaëlle Désaméricq, Guillaume Dolbeau, Christophe Verny, et al.
Pageof 11